Drug Trial Radar · NCT04106219
A Study of LY3295668 Erbumine in Participants With Relapsed/Refractory Neuroblastoma
Last checked: Nov 20, 2026Latest source record: Aug 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
71
Planned (sponsor's estimate)
Start
Jun 11, 2020
Primary completion
Apr 13, 2022
Study completion Aug 2027
Sponsor
- Lead sponsor
- Eli Lilly and CompanyEli Lilly (LLY)
- Sponsor type
- Industry
- Collaborators
- New Approaches to Neuroblastoma Therapy Consortium; Innovative Therapies for Children with Cancer in Europe (ITCC)
- First posted
- Sep 26, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 2 years, up to 21 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The reason for this study is to see if the study drug LY3295668 erbumine is safe in participants with relapsed/refractory neuroblastoma.
Conditions
- Neuroblastoma
Interventions
LY3295668 ErbumineDrug
Administered orally.
TopotecanDrug
Administered IV.
CyclophosphamideDrug
Administered IV.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants with Dose Limiting Toxicities (DLTs)Time frame: Baseline through Cycle 2 (28 Day Cycle)
- Overall Response Rate (ORR): Percentage of Participants Who Achieve Complete Response (CR) or Partial Response (PR)Time frame: Baseline through Measured Progressive Disease (Estimated up to 5 Years)
- Duration of Response (DoR)Time frame: Date of CR or PR to Date of Disease Progression or Death Due to Any Cause (Estimated up to 5 Years)
Locations
17 sites in 9 countries. Site status is shown where the registry gives one.
UCSF Medical Center at Mission Bay
San Francisco, California
Children's Hospital Colorado
Aurora, Colorado
University of Chicago - Comer Children's Hospital
Chicago, Illinois
Dana-Farber Cancer Institute
Boston, Massachusetts
Cincinnati Childrens Hospital Medical Center
Cincinnati, Ohio
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania
Texas Childrens Hospital
Houston, Texas
Perth Children's Hospital
Perth, Western Australia, Australia
UZ Gent
Ghent, Oost-Vlaanderen, Belgium
Institut Curie
Paris, France
Centre Leon Berard
Lyon, Auvergne-Rhône-Alpes, France
Universitätsklinikum Köln
Cologne, Germany
Istituto Nazionale dei Tumori
Milan, Lombardy, Italy
National Cancer Center Hospital
Chuo-ku, Tokyo, Japan
Hospital Infantil Universitario Niño Jesús
Madrid, Spain
Hospital Universitari Vall d'Hebron
Barcelona, Barcelona [Barcelona], Spain
Alder Hey Children's Hospital
Liverpool, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.